- Home
- UNP vs GILD Comparison
UNP vs GILD Comparison
Compare UNP & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UNP | GILD |
|---|---|---|
| Founded | 1862 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Railroads | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.9B | 184.4B |
| IPO Year | 2004 | 2001 |
Fundamental Metrics
Financial Performance| Metric | UNP | GILD |
|---|---|---|
| Price | $244.52 | $139.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 18 |
| Target Price | ★ $263.09 | $146.50 |
| AVG Volume (30 Days) | 2.5M | ★ 4.9M |
| Earning Date | 04-23-2026 | 04-23-2026 |
| Dividend Yield | 2.26% | ★ 2.35% |
| EPS Growth | 8.03 | ★ 1684.21 |
| EPS | ★ 11.98 | 6.78 |
| Revenue | $19,533,000,000.00 | ★ $24,689,000,000.00 |
| Revenue This Year | $4.22 | $4.69 |
| Revenue Next Year | $4.75 | $5.95 |
| P/E Ratio | ★ $20.41 | $20.59 |
| Revenue Growth | N/A | ★ 9.98 |
| 52 Week Low | $204.66 | $95.30 |
| 52 Week High | $268.14 | $157.29 |
Technical Indicators
Market Signals| Indicator | UNP | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 49.41 | 46.31 |
| Support Level | $218.03 | $108.90 |
| Resistance Level | $268.14 | $149.38 |
| Average True Range (ATR) | 4.36 | 3.41 |
| MACD | 0.53 | -0.14 |
| Stochastic Oscillator | 90.18 | 45.40 |
Price Performance
Historical ComparisonAbout UNP Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two-thirds of the US, Union Pacific generated $24 billion of revenue in 2024 by hauling coal, industrial products, intermodal containers, agricultural goods, chemicals, fertilizers, and automotive goods. Union Pacific owns about one-fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).